Teva Pharmaceutical (TEVA) analyst forecast and price target
Analyst forecast
Consensus of 13 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $42.00 from $40.00 | Aug 12, 2026 |
| Piper Sandler | Maintained | Overweight | $44.00 from $42.00 | Jul 28, 2026 |
| Barclays | Maintained | Overweight | $40.00 from $38.00 | May 6, 2026 |
| Truist Securities | Maintained | Buy | $45.00 from $42.00 | Apr 30, 2026 |
| Piper Sandler | Maintained | Overweight | $42.00 from $41.00 | Apr 30, 2026 |
| UBS | Maintained | Buy | $42.00 from $36.00 | Apr 30, 2026 |
| JP Morgan | Maintained | Overweight | $40.00 from $35.00 | Apr 30, 2026 |
| B of A Securities | Maintained | Buy | $42.00 from $38.00 | Apr 9, 2026 |
| Piper Sandler | Maintained | Overweight | $41.00 from $40.00 | Mar 4, 2026 |
| Truist Securities | Maintained | Buy | $42.00 from $38.00 | Feb 18, 2026 |
| Goldman Sachs | Maintained | Buy | $45.00 from $36.00 | Feb 9, 2026 |
| Barclays | Maintained | Overweight | $38.00 from $35.00 | Jan 30, 2026 |
| Truist Securities | Maintained | Buy | $38.00 from $36.00 | Jan 29, 2026 |
| Scotiabank | Maintained | Sector Outperform | $40.00 from $35.00 | Jan 29, 2026 |
| Jefferies | Maintained | Buy | $40.00 from $29.00 | Jan 6, 2026 |
| Piper Sandler | Maintained | Overweight | $40.00 from $30.00 | Dec 22, 2025 |
| Goldman Sachs | Maintained | Buy | $35.00 from $31.00 | Dec 19, 2025 |
| JP Morgan | Maintained | Overweight | $35.00 from $28.00 | Dec 16, 2025 |
| B of A Securities | Maintained | Buy | $32.00 from $29.00 | Dec 9, 2025 |
| Barclays | Initiated Coverage | Overweight | $35.00 | Dec 9, 2025 |
Frequently asked questions
Is TEVA a buy, sell, or hold?
Analysts covering Teva Pharmaceutical currently average a Buy rating: 13 buy, 0 hold and 0 sell, from 13 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on TEVA?
On Aug 12, 2026, Barclays maintained Teva Pharmaceutical at Overweight with a price target of $42.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.